Cipla today announced that its wholly-owned subsidiary in United Kingdom, Cipla (EU) (hereinafter together referred as Cipla) will invest an additional EUR 3 million in Ethris GmbH (Ethris), a global leader in delivering mRNAs directly to the respiratory system. This additional investment through a convertible loan will accelerate Cipla's participation in the mRNA space.
